BioTech Daily News

An independent publication not affililated with any other organization

Wednesday
June 25, 2014

2nd EDITION
San Diego • FREE

Credenz—More than a New Soybean Brand—A New Soybean Seed

Bayer CropScience is proud to introduce Credenz, its first entry into the global soybean seed market. The company talks about Credenz as more than a soybean seed but an innovation that represents decades of research and development to make it unique to the market.

"It's our innovative scientific approach to genetics, seed treatments and crop protection," according to Bayer CropScience, which makes Credenz so unique. Customers are buying more than a seed—they are buying an

continued on page 39

Protecting Your Most Valued Inventions: Bereskin & Parr LLP—Your Expert IP Team in Canada

Article Courtesy of Bereskin & Parr LLP

Innovation in the biotechnology and pharmaceutical industry creates new and exciting business opportunities. Therefore, the protection and enforcement of intellectual property rights is critical to making the most of your research and development. By staying at the forefront of trends and changes in the industry, Bereskin & Parr

continued on page 15

Cambridge Biomedical: Exploring the On-Shoring Versus Off-Shoring Decision

Dr. John Reddington was appointed Chief Operating Officer of Cambridge Biomedical in 2011

Previously Reddington served as president and CEO of Sirtex Medical, Inc., the US division of an Australian public company, Sirtex Medical Group Ltd. Prior to Sirtex, Reddington was COO and SVP of R&D for the public company Valentis, Inc., where he played a key role in transitioning Valentis' clinical focus from gene therapy to poloxamer-based

continued on page 37

Orphan Expert Dr. Timothy R. Coté Launches Regulatory Affairs Consulting Firm

Article Courtesy of Coté Orphan Consulting

Timothy R. Coté MD, MPH is one of the leading regulatory experts in orphan product development. During his 20-plus years in the field he has acquired extensive specialized knowledge of rare diseases and orphan drugs. Most notably, Coté recently served as the Director of FDA's Office of Orphan Products

continued on page 42

Gallus Expands Process Development Capacity

Gallus BioPharmaceuticals is a pure-play CMO, delivering a high level of quality and reliability in biologics manufacturing to clinical and commercial clients. Over the past year, Gallus has significantly enhanced its Process Development (PD) capabilities through acquisition and internal expansion. This growth provides Gallus' PD team flexibility in adjusting for project specific configurations enabling Gallus to achieve its vision of being the most trusted provider of world class biologics development and manufacturing services for the pharmaceutical and biotechnology industry.

A major PD expansion came when Gallus

continued on page 42

MassBio's Impact 2020 Report Holds Implications for Defining Health Care Value in the ACA Era and Beyond

Article Courtesy of MassBio

The Massachusetts Biotechnology Council (MassBio), the state industry association for the life sciences, has issued a call to action for stakeholders—across industry, academia, health care networks, payers and government—to take steps to safeguard the Commonwealth's

continued on page 22

BioBridge Global Diverse Capabilities and Innovative Solutions

Article Courtesy of BioBridge Global

BioBridge Global combines diverse capabilities with a coordinated approach to save and enhance lives around the world by providing products and services that meet vital medical needs. It is the parent company of three integrated nonprofit subsidiaries, GenCure, QualTex Laboratories and the South Texas Blood & Tissue Center, that offer innovative solutions in the areas of regenerative medicine, blood

continued on page 42

The Advantages of Processing Bio-Hazardous Medical Waste Using Red Bag Solutions' Technology

Whether you want to reduce costs, expand recycling, reduce risk of liability, enhance sustainability, or reduce your organization's carbon footprint, Red Bag Solutions' (RBS) technology and services offer a superior way to process and dispose of biohazardous medical waste.

Based in Baltimore, Maryland, USA, RBS has provided clients worldwide

continued on page 39

Cyto-Mine Single Cell Analysis and Monoclonality Assurance System: An Automated Platform Delivering High-Throughput, Novel Assays on Single Cells and Their Interactions

Sphere Fluidics Limited is an established, Life Sciences company, and has developed products for the generation, fusing, analysis, sorting and retrieval of small volumes (picolitre to

continued on page 28

BAYER CROPSCIENCE

(continued from page 1)

entire service and support system essentially "baked" into the seed.

Other technologies brought by Bayer make looking at soybeans a whole new experience: Poncho/VOTiVO, FOX, Liberty/LibertyLink and Balance GT, along with the company's experience in the cotton and canola seed markets.

Let's start with Poncho/VOTiVO for healthier plant establishment and yield. Powerful control and protection when the plant needs it most—when it's young.

FOX: Helping to treat the real problem of Asian Soybean Rust (ASR), which managed to completely change soybean management in Brazil between 2003 and 2012 when it led to losses of USD 25 billion in Brazil alone.

Since the launch of this product in the 2011/12 season Fox has successfully treated 20 million hectares and Bayer CropScience is making a significant investment into the production capacity expansion to meet current and future need to support soybean growers in Brazil.

The LibertyLink system is an advanced weed control system with powerful control and high performing germplasm that growers you ahead of the curve. Bayer CropScience plans to introduce this technology into Latin America in the next 2-3 years so soybean growers there can benefit from its advanced properties in sustained weed control, unique mode of action and control of ALS-and glyphosate-resistant weeds.

The Balance GT Soybean Performance System Bayer will provide in the future pending deregulation provides high-yielding elite soybean genetics, double herbicide tolerant stack allowing the use of two active ingredients with different modes of action, glyphosate and Balance Bean, for additional herbicide flexibility and residual control with reactivation technology, low volatility and use rates.

"Credenz soybean seed will help us deliver growers improved soybean varieties, along with future traits that could protect them against specific insects, repel persistent attacks by nematodes and make them tolerant to the most effective herbicides," said Alfonso Alba Ordonez, Global Head Soybeans & Corn and Head of Seed Operations Latin America.

For more information, stop by Booth #1727.

RED BAG

(continued from page 1)

with the Steam Sterilization and Maceration System (SSM) for more than 18 years. Steam is recognized worldwide as an accepted standard for sterilizing biohazardous medical waste.

And the SSM system is designed for safe and cost-effective processing of a broad variety of medical waste, including:

- Biological agents and infectious materials,
- Needles, syringes, and disposable surgical instruments,
- Sharps containers and needle boxes,
- Confidential media and proprietary materials,
- Blood products and body fluids,
- Pathogens: bacterial, viral, fungi and other infectious agents,
- Contaminated animal carcasses and animal bedding, and
- Some pharmaceuticals.

With the SSM system, bio-hazardous medical waste is macerated and simultaneously surrounded by superheated water and steam until sterilization is achieved. The waste is made unrecognizable, while its volume and weight is reduced by up to 90 percent and 30 percent respectively. Once processed, solid waste is guaranteed sterile, safe and classified as ordinary municipal trash, while liquids are discharged into the sanitary sewer and completely accepted by all local regulatory agencies. Confidential material such as labels, CD's, microfilm and other media is completely destroyed and is no longer recognizable.

The environmentally friendly SSM is a completely closed system, so it processes waste without odor, without chemicals and without any negative air emissions. This 100 percent regulatory compliant technology is friendly to the internal environment, operating at less than 80 decibels.

SSM is easy to install and has a smaller footprint than other on-site medical waste processing technologies. SSM requires 250 square feet with minimum ceiling height of 9 feet. And SSM is built to last. With proper maintenance, its operational life expectancy is at least ten years.

SSM is safe and easy to operate. It is controlled by a Program Logic Control (PLC) system, allowing for minimal operator involvement. This control system also allows RBS to monitor the system 24/7 via the Internet for predictive and preventive maintenance using RBS' propriety software.

Besides the use by hospitals and Clinical Labs, Pharmaceutical and Bio Technology companies have also found the SSM to be advantageous for mitigating risk and reducing costs. An example of RBS' Bio/Pharm related clients who have installed SSM are: CEVA Biomune, Genzyme/Sanofi, Shire, USDA, American Red Cross, Medimmune, National Cancer Institute, etc.

Red Bag Solutions offers customizable options to support the acquisition and operation of SSM's proven technology. Your company does not need to invest its cash in order to realize the many benefits provided by SSM. Red Bag Solutions offers Turnkey Service Agreements that can reduce your cost to dispose of bio-hazardous waste from the first day SSM is operational in your facility. For more information visit Booth #2305, www.redbag.com or contact Eric Fox, Red Bag Solutions at 949-439-4544 or call 877-973-3224.

Pictured on cover: The Red Bag SSM simultaneously cuts and sterilizes biohazardous medical waste on-site. SSM processed waste is sterilized, safe and unrecognizable. It can be recycled or placed in a municipal landfill. Eliminates the potential liability associated with spills and mishandling during transport of bio-hazardous waste. SSM-processed material is guaranteed safe before it leaves your premises. The system is easy to install, in approximately 300 square feet, economical, and can be implemented with no capital outlay. It produces no objectionable odors and uses no harmful chemicals.

AAIPHARMA SERVICES CORP.

(continued from page 6)

Global Healthcare, of Ecolab Inc. She also serves on the boards of directors of American Capital, Ltd. and Hormel Foods Corporation.

About AAIPharma Services Corp. and Cambridge Major Laboratories, Inc.

AAIPharma Services Corp. and Cambridge Major Laboratories, Inc. have joined to form a world-class supplier of comprehensive pharmaceutical development and manufacturing services. With nearly 800 employees operating out of seven sites in the U.S. and Europe, combined capabilities include API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (solid dose and parenteral), packaging, and stability services. The Companies are portfolio companies of American Capital, Ltd. (NASDAQ: ACAS).

For more information on the companies, visit www.aaipharma.com and www.c-mlabs.com.

TEXAS BIOMED

(continued from page 8)

both malaria and schistosomiasis, potentially opening the door to the development of new therapies for these devastating diseases. These same techniques can be employed to investigate the genetic basis of biomedically important traits in these parasites or in other pathogenic organisms, and Texas Biomed is interested in collaborating with outside organizations in this area.

Second, Dr. Andrew Hayhurst in our Department of Virology and Immunology has invented a methodology for rapid identification of recombinant llama antibody pairs suitable for use in sandwich ELISA assays, reducing the time to develop these assays to days instead of months. The process reduces the need for protein purification and modification for ELISA screening, thereby saving costs and increasing throughput. In addition, these antibodies are temperature stable, allowing the use of the resultant assays under harsh field conditions in remote areas without the need for refrigeration of reagents. This technology is available for licensing from Texas Biomed.

Please visit Texas Biomed, Booth #654. For further information, contact Cliff Hendrick: 303-895-8216 or chendrick@txbiomed.org.

ACELRX PHARMACEUTICALS

(continued from page 25)

President from August 2004 to November 2004 for Questcor Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development, acquisition and marketing of pharmaceutical products. Morris graduated cum laude with a BS in Business with emphasis in Accounting from California State University, Chico, and is a Certified Public Accountant.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. AcelRx has announced positive results from each of the three completed Phase 3 clinical trials for Zalviso, and has submitted an NDA to the FDA seeking approval for Zalviso in the treatment of moderate-to-severe acute pain in adult patients in the hospital setting. AcelRx plans to initiate a Phase 3 clinical trial for ARX-04, a product candidate for the treatment of moderate-to-severe acute pain in a medically supervised setting, during the second half of 2014. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.

For additional information about AcelRx's clinical programs, please visit www.acelrx.com.

Innovative Alternatives for Biohazardous Waste Management

BIO INTERNATIONAL CONVENTION BOOTH #2305

RED BAG SOLUTIONS STEAM STERILIZATION SYSTEM

TURNS MEDICAL WASTE INTO UNRECOGNIZABLE, STERILIZED CONFETTI.

A GREEN SOLUTION IN A RED BOX

PROTECT
THE ENVIRONMENT WITH SUSTAINABLE SOLUTIONS

PROCESS
MEDICAL WASTE ON-SITE

GUARANTEE
STERILIZATION

REDUCE
LONG-TERM LIABILITY

Environmentally Friendly and Cost-Effective Solution for the Destruction of Biomedical Waste and Confidential Documents.

All types of medical waste converted to unregonizable, sterile, recyclable materials.

Processes all Types of Waste with Substantial Decreases in Liability and Green House Gas Production



Compare Sustainabilty With Our Online Calculator at http://redbag.com/sustain

- ☑ Complete Sterilization
- ☑ No Odors or Negative Air Emissions
- ☑ Minimum Noise
- ☑ Easy Installation
- ☑ Transforms Waste to Municipal Trash
- ☑ Uses Steam or Ozone
- ☑ Huge Reduction in Carbon Footprint
- ☑ Rapid, Measurable Cost Reduction
- ☑ Requires Only 250 Square Feet
- ☑ No Negative Environmental Impact

Red Bag Solutions, Inc.
3431 Benson Avenue
Suite 100
Baltimore, MD 21227 USA
Email: sales@redbag.com

REDBAG.COM / 877-973-3224